![]() Investors should not hesitate to add MCK to their portfolio. CAH is barely ranked in the top half of its space. Furthermore, MCK is ranked in the top 10 of its segment. Of the 16 analysts who have issued CAH recommendations, two consider the stock a Strong Buy, four consider it a Buy, and 10 consider it a Hold. CAH’s average upside potential has been 13% in the past 13 months. The stock’s average price target has increased $1.86 across the prior 32 weeks. The highest analyst target price for CAH is $74. The lowest analyst target price for CAH is $56. If CAH hits this price, it will have popped by slightly more than 10%. You can find out more about the stocks in this space by clicking here.ĬAH has an average analyst target price of $63.36. Unauthorized use prohibited 17-5B Images courtesy of Cardinal Health. Click here to find out how CAH fares in the Stability component of the POWR Ratings.ĬAH is ranked 30th of 77 stocks in the Medical – Services segment. MD/Custom Medical Stock Photo 1-7A (left and right) Courtesy ofDarci Manley. The stock has a B grade in the Value component of the POWR Ratings. CAH has C grades in the Momentum, Quality, Sentiment, and Growth components. This grade indicates the stock is a Hold. CAH has a beta of 1.06, meaning it probably won’t fluctuate much in the event that the market significantly undulates moving forward.ĬAH has a C POWR Rating. This low figure indicates CAH might be a bit undervalued at $56.68 per share. The stock has a forward P/E ratio of 9.60. ![]() CAH’s pharmaceutical segment is the second-largest in the country. If the stock hits the analysts’ average target price, it will have increased by slightly more than 19% in value.īased in Dublin, Ohio, CAH is a countrywide distributor and provider of services for pharmacies, prescription drug manufacturers, and healthcare providers. The lowest analyst target price for MCK is $205 while the highest target price is $257. The average analyst price target for the stock is $225.53. You can find out more about the publicly traded companies in this space by clicking here. MCK is ranked in the top 10 of its Medical – Services industry, landing at number 10 out of 77 stocks in the segment. Click here to find out how MCK grades out in the Sentiment and Growth components of the POWR Ratings. MCK has Cs in the Momentum and Quality components of the POWR Ratings. The stock has Bs in the Value and Stability components of the POWR Ratings. MCK has a beta of 0.88 so it will likely maintain most of its value even if the market significantly declines. This means the stock might be undervalued at $191.03.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |